Cargando…

Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study

INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane-bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated...

Descripción completa

Detalles Bibliográficos
Autores principales: Haupt, Thomas Huneck, Petersen, Janne, Ellekilde, Gertrude, Klausen, Henrik Hedegaard, Thorball, Christian Wandall, Eugen-Olsen, Jesper, Andersen, Ove
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580714/
https://www.ncbi.nlm.nih.gov/pubmed/22824423
http://dx.doi.org/10.1186/cc11434
_version_ 1782260314122747904
author Haupt, Thomas Huneck
Petersen, Janne
Ellekilde, Gertrude
Klausen, Henrik Hedegaard
Thorball, Christian Wandall
Eugen-Olsen, Jesper
Andersen, Ove
author_facet Haupt, Thomas Huneck
Petersen, Janne
Ellekilde, Gertrude
Klausen, Henrik Hedegaard
Thorball, Christian Wandall
Eugen-Olsen, Jesper
Andersen, Ove
author_sort Haupt, Thomas Huneck
collection PubMed
description INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane-bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade inflammation marker reflecting on disease severity. The aim of this prospective observational study was to determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/Charlson Comorbidity Index Score, and mortality. METHODS: We included 543 patients with various diseases from a Danish Acute Medical Unit during a two month period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion by their unique civil registry number and using Danish registries to determine admission times, readmissions, International Classification of Diseases, 10(th )Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to determine suPAR's association with these endpoints. RESULTS: Increased suPAR was significantly associated with 90-day mortality (4.87 ng/ml in survivors versus 7.29 ng/ml in non-survivors, P < 0.0001), higher Charlson Score (P < 0.0001), and longer admission time (P < 0.0001), but not with readmissions. The association with mortality remained when adjusting for age, sex, C-reactive protein (CRP), and Charlson Score. Furthermore, among the various Charlson Score disease groups, suPAR was significantly higher in those with diabetes, cancer, cardiovascular disease, and liver disease compared to those without comorbidities. CONCLUSIONS: SuPAR is a marker of disease severity, admission time, and risk of mortality in a heterogeneous cohort of patients with a variety of diseases. The independent value of suPAR suggests it could be of value in prognostic algorithms.
format Online
Article
Text
id pubmed-3580714
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35807142013-02-26 Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study Haupt, Thomas Huneck Petersen, Janne Ellekilde, Gertrude Klausen, Henrik Hedegaard Thorball, Christian Wandall Eugen-Olsen, Jesper Andersen, Ove Crit Care Research INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane-bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade inflammation marker reflecting on disease severity. The aim of this prospective observational study was to determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/Charlson Comorbidity Index Score, and mortality. METHODS: We included 543 patients with various diseases from a Danish Acute Medical Unit during a two month period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion by their unique civil registry number and using Danish registries to determine admission times, readmissions, International Classification of Diseases, 10(th )Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to determine suPAR's association with these endpoints. RESULTS: Increased suPAR was significantly associated with 90-day mortality (4.87 ng/ml in survivors versus 7.29 ng/ml in non-survivors, P < 0.0001), higher Charlson Score (P < 0.0001), and longer admission time (P < 0.0001), but not with readmissions. The association with mortality remained when adjusting for age, sex, C-reactive protein (CRP), and Charlson Score. Furthermore, among the various Charlson Score disease groups, suPAR was significantly higher in those with diabetes, cancer, cardiovascular disease, and liver disease compared to those without comorbidities. CONCLUSIONS: SuPAR is a marker of disease severity, admission time, and risk of mortality in a heterogeneous cohort of patients with a variety of diseases. The independent value of suPAR suggests it could be of value in prognostic algorithms. BioMed Central 2012 2012-07-23 /pmc/articles/PMC3580714/ /pubmed/22824423 http://dx.doi.org/10.1186/cc11434 Text en Copyright ©2012 Haupt et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Haupt, Thomas Huneck
Petersen, Janne
Ellekilde, Gertrude
Klausen, Henrik Hedegaard
Thorball, Christian Wandall
Eugen-Olsen, Jesper
Andersen, Ove
Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study
title Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study
title_full Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study
title_fullStr Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study
title_full_unstemmed Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study
title_short Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study
title_sort plasma supar levels are associated with mortality, admission time, and charlson comorbidity index in the acutely admitted medical patient: a prospective observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580714/
https://www.ncbi.nlm.nih.gov/pubmed/22824423
http://dx.doi.org/10.1186/cc11434
work_keys_str_mv AT hauptthomashuneck plasmasuparlevelsareassociatedwithmortalityadmissiontimeandcharlsoncomorbidityindexintheacutelyadmittedmedicalpatientaprospectiveobservationalstudy
AT petersenjanne plasmasuparlevelsareassociatedwithmortalityadmissiontimeandcharlsoncomorbidityindexintheacutelyadmittedmedicalpatientaprospectiveobservationalstudy
AT ellekildegertrude plasmasuparlevelsareassociatedwithmortalityadmissiontimeandcharlsoncomorbidityindexintheacutelyadmittedmedicalpatientaprospectiveobservationalstudy
AT klausenhenrikhedegaard plasmasuparlevelsareassociatedwithmortalityadmissiontimeandcharlsoncomorbidityindexintheacutelyadmittedmedicalpatientaprospectiveobservationalstudy
AT thorballchristianwandall plasmasuparlevelsareassociatedwithmortalityadmissiontimeandcharlsoncomorbidityindexintheacutelyadmittedmedicalpatientaprospectiveobservationalstudy
AT eugenolsenjesper plasmasuparlevelsareassociatedwithmortalityadmissiontimeandcharlsoncomorbidityindexintheacutelyadmittedmedicalpatientaprospectiveobservationalstudy
AT andersenove plasmasuparlevelsareassociatedwithmortalityadmissiontimeandcharlsoncomorbidityindexintheacutelyadmittedmedicalpatientaprospectiveobservationalstudy